Becton, Dickinson and Company $BDX Position Boosted by Evelyn Partners Investment Management Europe Ltd

Evelyn Partners Investment Management Europe Ltd lifted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 1,417.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,017 shares of the medical instruments supplier’s stock after purchasing an additional 950 shares during the period. Evelyn Partners Investment Management Europe Ltd’s holdings in Becton, Dickinson and Company were worth $175,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in BDX. Saudi Central Bank bought a new position in shares of Becton, Dickinson and Company in the first quarter valued at $26,000. Kelly Lawrence W & Associates Inc. CA acquired a new position in shares of Becton, Dickinson and Company in the 1st quarter worth $31,000. Bell Investment Advisors Inc raised its position in shares of Becton, Dickinson and Company by 474.1% during the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 128 shares during the period. WPG Advisers LLC purchased a new stake in shares of Becton, Dickinson and Company during the first quarter valued at $36,000. Finally, Clal Insurance Enterprises Holdings Ltd boosted its position in shares of Becton, Dickinson and Company by 378.9% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 182 shares of the medical instruments supplier’s stock valued at $42,000 after purchasing an additional 144 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on BDX. Wall Street Zen lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Royal Bank Of Canada decreased their price objective on shares of Becton, Dickinson and Company from $211.00 to $202.00 and set a “sector perform” rating for the company in a research note on Friday, November 7th. Piper Sandler lowered their price objective on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research report on Friday, November 7th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Finally, Wells Fargo & Company upped their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research report on Friday, August 8th. Three analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, Becton, Dickinson and Company has an average rating of “Hold” and an average target price of $203.27.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $192.57 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The firm has a market cap of $55.20 billion, a PE ratio of 34.63, a PEG ratio of 1.42 and a beta of 0.25. The firm’s 50 day moving average price is $186.83 and its 200 day moving average price is $182.21. Becton, Dickinson and Company has a twelve month low of $162.29 and a twelve month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company had revenue of $5.32 billion for the quarter. As a group, research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th will be paid a dividend of $1.05 per share. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date is Monday, December 8th. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is currently 72.04%.

Insider Transactions at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director owned 22,226 shares of the company’s stock, valued at $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Bertram L. Scott sold 217 shares of the business’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the sale, the director owned 35,816 shares of the company’s stock, valued at $6,324,389.28. The trade was a 0.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 1,249 shares of company stock worth $231,358. 0.36% of the stock is currently owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.